{"disease":{"id":"stability","name":"stability"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Microsatellite instability-high colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"ipilimumab","indication_name":"Microsatellite instability-high colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"immuno-oncology-io","indication_name":"Microsatellite Instability-High (MSI-H) Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"yervoy","indication_name":"Microsatellite instability-high colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1789844","indication_name":"Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"pf-06865571","indication_name":"Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer in adults in combination with nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and bevacizumab and cetuximab and panitumumab and avelumab and pembrolizumab and nivolumab and ipilimumab and fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFOX6) and avelumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab and ipilimumab and pembrolizumab and nivolumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"fluorescein","indication_name":"Tear film stability testing","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fluorescite","generic_name":"FLUORESCEIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19","drug_class":"Diagnostic Dye","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"pembrolizuma","indication_name":"Microsatellite instability-high colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pembrolizuma","company_name":"Memorial Sloan Kettering Cancer Center","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":28,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05893420","title":"A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30000,"lead_sponsor_name":"AgileMD, Inc.","has_results":false},{"nct_id":"NCT06238193","title":"Molecular Characteristics of Early-onset Compared With Late-onset Colorectal Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":11344,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07405827","title":"French Shoulder Instability Surgery Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Chirurgie Du Sport","has_results":false},{"nct_id":"NCT07188363","title":"French Ankle Ligament Surgery Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Chirurgie Du Sport","has_results":false},{"nct_id":"NCT05476185","title":"USCRI READY4Life Program","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4800,"lead_sponsor_name":"US Committee for Refugees and Immigrants","has_results":false},{"nct_id":"NCT03616054","title":"International Observational Study on Airway Management in Critically Ill Patients","phase":"","overall_status":"COMPLETED","enrollment_count":3600,"lead_sponsor_name":"Azienda Ospedaliera San Gerardo di Monza","has_results":false},{"nct_id":"NCT05797298","title":"Toric Intraocular Lens (IOL) Implantation for Management of Cataracts","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Eye & ENT Hospital of Fudan University","has_results":false},{"nct_id":"NCT03786497","title":"Protecting Brains and Saving Futures - the PBSF Protocol","phase":"","overall_status":"UNKNOWN","enrollment_count":2268,"lead_sponsor_name":"Protecting Brains Saving Futures","has_results":false},{"nct_id":"NCT04319965","title":"Complications Related to Transpulmonary Thermodilution","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Bicetre Hospital","has_results":false},{"nct_id":"NCT06415006","title":"Can Shock Indices Be Prognostic Indicators in Sepsis/Septic Shock?","phase":"","overall_status":"COMPLETED","enrollment_count":1522,"lead_sponsor_name":"Başakşehir Çam & Sakura City Hospital","has_results":false},{"nct_id":"NCT03935750","title":"STABILITY 2: Anterior Cruciate Ligament Reconstruction +/- Lateral Tenodesis With Patellar vs Quad Tendon","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1236,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT04972526","title":"Resuscitative TEE Collaborative Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT06355635","title":"Application and Monitoring of Vasoactive and Inotrope Drugs","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Johannes Gutenberg University Mainz","has_results":false},{"nct_id":"NCT06446778","title":"Pipeline Embolization for Intracranial Aneurysms","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT04779619","title":"Exploring a New Measure of Emotion Regulation","phase":"","overall_status":"UNKNOWN","enrollment_count":903,"lead_sponsor_name":"Sussex Partnership NHS Foundation Trust","has_results":false},{"nct_id":"NCT04574908","title":"A Pilot Trial of Continuous Portable Postoperative Hemodynamic And Saturation Monitoring On Hospital Wards","phase":"NA","overall_status":"COMPLETED","enrollment_count":879,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":true},{"nct_id":"NCT05942157","title":"Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections","phase":"NA","overall_status":"UNKNOWN","enrollment_count":810,"lead_sponsor_name":"Singapore General Hospital","has_results":false},{"nct_id":"NCT03141099","title":"Blood Pressure and OXygenation Targets After OHCA","phase":"NA","overall_status":"COMPLETED","enrollment_count":802,"lead_sponsor_name":"Jesper Kjaergaard","has_results":false},{"nct_id":"NCT07470372","title":"Experimental Trial of an Employment-Based Housing Program for Adults at Risk of Homelessness: Housing Integrated With Residential Employment","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":750,"lead_sponsor_name":"The University of Texas Health Science Center, Houston","has_results":false},{"nct_id":"NCT06294054","title":"Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy","phase":"","overall_status":"UNKNOWN","enrollment_count":707,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT04482608","title":"The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival","phase":"","overall_status":"COMPLETED","enrollment_count":671,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05078047","title":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":646,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT06353854","title":"Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Federation Francophone de Cancerologie Digestive","has_results":false},{"nct_id":"NCT05919264","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":595,"lead_sponsor_name":"Parabilis Medicines, Inc.","has_results":false},{"nct_id":"NCT04644601","title":"Italian Version of The Cumberland Ankle Instability Tool (CAIT)","phase":"","overall_status":"COMPLETED","enrollment_count":550,"lead_sponsor_name":"University of Bologna","has_results":false},{"nct_id":"NCT03533205","title":"Prediction of Hemodynamic Instability in Patients Undergoing Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":507,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT05448092","title":"Registry for Evaluation of Lumbar Arthrodesis Sagittal alignmEnt","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Unit of neurosurgery, Departement of Neurosciences, University of Torino","has_results":false},{"nct_id":"NCT04191252","title":"Genetic Mutation in Epithelial Ovarian Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT07403721","title":"AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":464,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT02955485","title":"A Prediction Model for Chronic Ankle Instability","phase":"","overall_status":"TERMINATED","enrollment_count":460,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT02178722","title":"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04220359","title":"Early Identification of Clinical Deterioration Using a Wearable Monitoring Device","phase":"","overall_status":"COMPLETED","enrollment_count":410,"lead_sponsor_name":"Biobeat Technologies Ltd.","has_results":false},{"nct_id":"NCT05648474","title":"Intraoperative Monitoring for the Lateral Lumbar Interbody Fusion Procedure","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Alphatec Spine, Inc.","has_results":false},{"nct_id":"NCT06269471","title":"On the ICC's Path: a Prevalence Study","phase":"","overall_status":"UNKNOWN","enrollment_count":385,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT05336357","title":"Non-invasive Goal-directed thErapy oN cIrcUlatory Shock","phase":"NA","overall_status":"RECRUITING","enrollment_count":380,"lead_sponsor_name":"University of Sao Paulo","has_results":false},{"nct_id":"NCT03021525","title":"Individualized Perioperative Hemodynamic Goal-directed Therapy in Major Abdominal Surgery (iPEGASUS-trial)","phase":"NA","overall_status":"COMPLETED","enrollment_count":380,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT02332668","title":"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":370,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT05451381","title":"Vasopressor Requirements Depends on Sedation Strategy","phase":"NA","overall_status":"COMPLETED","enrollment_count":356,"lead_sponsor_name":"Anesthesia Research Group UA","has_results":false},{"nct_id":"NCT04828096","title":"Retention With Three Different Bonded Retainers a Multicenter, Randomized Controlled Trial With 5-year Follow-up","phase":"NA","overall_status":"RECRUITING","enrollment_count":324,"lead_sponsor_name":"Region Örebro County","has_results":false},{"nct_id":"NCT07054151","title":"Clinical Predictors of Capillary Refill Time and Their Association With Triage Categories","phase":"","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Izmir Democracy University","has_results":false},{"nct_id":"NCT04999904","title":"A Proprioceptive Training Program Using an Uneven Terrain Treadmill for Patients With Ankle Instability","phase":"NA","overall_status":"RECRUITING","enrollment_count":312,"lead_sponsor_name":"Henry M. Jackson Foundation for the Advancement of Military Medicine","has_results":false},{"nct_id":"NCT04972331","title":"Automated AI Voice Calls for Postoperative Follow-up After Arthroscopic Shoulder Instability Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":310,"lead_sponsor_name":"Institut de Chirurgie Reparatrice Locomoteur et Sports","has_results":false},{"nct_id":"NCT05310357","title":"Chromosomal Instability in Ovarian Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT04191226","title":"Genetic Mutation in Recurrent Cervical Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT03985839","title":"Safety and Performance of MICRORAPTOR™ Suture Anchors in Shoulder and Hip","phase":"","overall_status":"COMPLETED","enrollment_count":299,"lead_sponsor_name":"Smith & Nephew, Inc.","has_results":false},{"nct_id":"NCT06477718","title":"Genomic Signatures for Patients With Initially Unresectable Colorectal Liver Metastases","phase":"","overall_status":"COMPLETED","enrollment_count":286,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT04064502","title":"Chronıc Ankle Instabılıty And Assocıated Factors","phase":"","overall_status":"COMPLETED","enrollment_count":273,"lead_sponsor_name":"Yeditepe University","has_results":false},{"nct_id":"NCT03926338","title":"Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03012581","title":"Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT04401345","title":"Effect of Glycopyrrolate on Vasopressors Requirement for Non-elective Caesarean Section Under Spinal Anaesthesia","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":258,"lead_sponsor_name":"Rajesh Deshar","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}